8 results on '"Vergara, Ander"'
Search Results
2. Safety of Obtaining an Extra Biobank Kidney Biopsy Core
- Author
-
Bermejo, Sheila, primary, García-Carro, Clara, additional, Mast, Richard, additional, Vergara, Ander, additional, Agraz, Irene, additional, León, Juan Carlos, additional, Bolufer, Monica, additional, Gabaldon, Maria-Alejandra, additional, Serón, Daniel, additional, Bestard, Oriol, additional, and Soler, Maria Jose, additional
- Published
- 2022
- Full Text
- View/download PDF
3. The Impact of Age on Mortality in Chronic Haemodialysis Population with COVID-19
- Author
-
Vergara, Ander, primary, Molina-Van den Bosch, Mireia, additional, Toapanta, Néstor, additional, Villegas, Andrés, additional, Sánchez-Cámara, Luis, additional, Sequera, Patricia, additional, Manrique, Joaquín, additional, Shabaka, Amir, additional, Aragoncillo, Inés, additional, Ruiz, María, additional, Benito, Silvia, additional, Sánchez, Emilio, additional, and Soler, María, additional
- Published
- 2021
- Full Text
- View/download PDF
4. How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR
- Author
-
García-Carro, Clara, primary, Vergara, Ander, additional, Bermejo, Sheila, additional, Azancot, María A., additional, Sánchez-Fructuoso, Ana I., additional, Sánchez de la Nieta, M. Dolores, additional, Agraz, Irene, additional, and Soler, María José, additional
- Published
- 2021
- Full Text
- View/download PDF
5. A Specific Tubular ApoA-I Distribution Is Associated to FSGS Recurrence after Kidney Transplantation
- Author
-
Jacobs-Cachá, Conxita, primary, Puig-Gay, Natàlia, additional, Vergara, Ander, additional, Gabaldon, Maria-Alejandra, additional, Sellarés, Joana, additional, Villena-Ortiz, Yolanda, additional, Agraz, Irene, additional, Moreso, Francesc, additional, Soler, Maria José, additional, Serón, Daniel, additional, and López-Hellín, Joan, additional
- Published
- 2021
- Full Text
- View/download PDF
6. The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes
- Author
-
García-Carro, Clara, Vergara, Ander, Agraz Pamplona, Irene, Jacobs-Cachá, Conxita, Espinel, Eugenia, Seron, Daniel, Soler, María José, Universitat Autònoma de Barcelona, Institut Català de la Salut, [García-Carro C, Vergara A] Grup de Recerca en Nefrologia, Vall d’Hebron Institut de Recerca, Barcelona, Spain. Servei de Nefrologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Agraz I, Jacobs-Cachá C, Espinel E, Seron D, Soler MJ] Grup de Recerca en Nefrologia, Vall d’Hebron Institut de Recerca, Barcelona, Spain. Servei de Nefrologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. Red de Investigación Renal (REDINREN), Instituto Carlos III, Madrid, Spain., and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Nefropaties diabètiques - Fisiologia patològica ,Sodium-glucose co-transporter 2 inhibitors ,Otros calificadores::/fisiología [Otros calificadores] ,Other subheadings::/physiology [Other subheadings] ,lcsh:Medicine ,030209 endocrinology & metabolism ,sodium-glucose co-transporter 2 inhibitors ,Type 2 diabetes ,Disease ,Review ,dipeptidyl peptidase 4 inhibitors ,030204 cardiovascular system & hematology ,Other subheadings::Other subheadings::/drug therapy [Other subheadings] ,Bioinformatics ,acciones y usos químicos::acciones farmacológicas::acciones y usos químicos::acciones farmacológicas::efectos fisiológicos de los fármacos::hipoglicemiantes::inhibidores de la dipeptidil-peptidasa IV [COMPUESTOS QUÍMICOS Y DROGAS] ,Glucagon-like peptide-1 receptor agonists ,Endocrine System Diseases::Diabetes Mellitus::Diabetes Complications::Diabetic Nephropathies [DISEASES] ,Chemical Actions and Uses::Pharmacologic Actions::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Hypoglycemic Agents::Dipeptidyl-Peptidase IV Inhibitors [CHEMICALS AND DRUGS] ,03 medical and health sciences ,0302 clinical medicine ,reno-cardiovascular protection ,Diabetes management ,Diabetes mellitus ,medicine ,Nefropaties diabètiques - Tractament ,Other subheadings::/therapeutic use [Other subheadings] ,Diabetic kidney disease ,Reno-cardiovascular protection ,Dipeptidyl peptidase-4 ,Otros calificadores::Otros calificadores::/tratamiento farmacológico [Otros calificadores] ,glucagon-like peptide-1 receptor agonists ,diabetes ,Otros calificadores::/uso terapéutico [Otros calificadores] ,business.industry ,lcsh:R ,Diabetes ,General Medicine ,medicine.disease ,Antidiabètics - Ús terapèutic ,diabetic kidney disease ,enfermedades del sistema endocrino::diabetes mellitus::complicaciones de la diabetes::nefropatías diabéticas [ENFERMEDADES] ,Dipeptidyl peptidase 4 inhibitors ,Heart failure ,Albuminuria ,medicine.symptom ,business ,Kidney disease - Abstract
Diabetes; Diabetic kidney disease; Dipeptidyl peptidase 4 inhibitors Diabetis; Nefropatia diabètica; Inhibidors de la dipeptidil peptidasa 4 Diabetes; Nefropatía diabética; Inhibidores de la dipeptidil peptidasa 4 Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease in the developed world. Until 2016, the only treatment that was clearly demonstrated to delay the DKD was the renin-angiotensin system blockade, either by angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. However, this strategy only partially covered the DKD progression. Thus, new strategies for reno-cardiovascular protection in type 2 diabetic patients are urgently needed. In the last few years, hypoglycaemic drugs, such as sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, demonstrated a cardioprotective effect, mainly in terms of decreasing hospitalization for heart failure and cardiovascular death in type 2 diabetic patients. In addition, these drugs also demonstrated a clear renoprotective effect by delaying DKD progression and decreasing albuminuria. Another hypoglycaemic drug class, dipeptidyl peptidase 4 inhibitors, has been approved for its use in patients with advanced chronic kidney disease, avoiding, in part, the need for insulinization in this group of DKD patients. Studies in diabetic and non-diabetic experimental models suggest that these drugs may exert their reno-cardiovascular protective effect by glucose and non-glucose dependent mechanisms. This review focuses on newly demonstrated strategies that have shown reno-cardiovascular benefits in type 2 diabetes and that may change diabetes management algorithms. The authors are current recipients of research grants from the FONDO DE INVESTIGACIÓN SANITARIA-FEDER, ISCIII, PI17/00257, and REDINREN, RD16/0009/0030.
- Published
- 2019
7. Matrix Metalloproteinases in Diabetic Kidney Disease.
- Author
-
Garcia-Fernandez, Nuria, Jacobs-Cachá, Conxita, Mora-Gutiérrez, José María, Vergara, Ander, Orbe, Josune, and Soler, María José
- Subjects
DIABETIC nephropathies ,MATRIX metalloproteinases ,RENAL circulation ,PATHOLOGY ,CHRONIC kidney failure - Abstract
Around the world diabetic kidney disease (DKD) is the main cause of chronic kidney disease (CKD), which is characterized by mesangial expansion, glomerulosclerosis, tubular atrophy, and interstitial fibrosis. The hallmark of the pathogenesis of DKD is an increased extracellular matrix (ECM) accumulation causing thickening of the glomerular and tubular basement membranes, mesangial expansion, sclerosis, and tubulointerstitial fibrosis. The matrix metalloproteases (MMPs) family are composed of zinc-dependent enzymes involved in the degradation and hydrolysis of ECM components. Several MMPs are expressed in the kidney; nephron compartments, vasculature and connective tissue. Given their important role in DKD, several studies have been performed in patients with DKD proposing that the measurement of their activity in serum or in urine may become in the future markers of early DKD. Studies from diabetic nephropathy experimental models suggest that a balance between MMPs levels and their inhibitors is needed to maintain renal homeostasis. This review focuses in the importance of the MMPs within the kidney and their modifications at the circulation, kidney and urine in patients with DKD. We also cover the most important studies performed in experimental models of diabetes in terms of MMPs levels, renal expression and its down-regulation effect. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. The Impact of Age on Mortality in Chronic Haemodialysis Popu-Lation with COVID-19.
- Author
-
Vergara A, Molina-Van den Bosch M, Toapanta N, Villegas A, Sánchez-Cámara L, Sequera P, Manrique J, Shabaka A, Aragoncillo I, Ruiz MC, Benito S, Sánchez E, and Soler MJ
- Abstract
Age and chronic kidney disease have been described as mortality risk factors for coronavirus disease 2019 (COVID-19). Currently, an important percentage of patients in haemodialysis are elderly. Herein, we investigated the impact of age on mortality among haemodialysis patients with COVID-19. Data was obtained from the Spanish COVID-19 chronic kidney disease (CKD) Working Group Registry. From 18 March 2020 to 27 August 2020, 930 patients on haemodialysis affected by COVID-19 were included in the Registry. A total of 254 patients were under 65 years old and 676 were 65 years or older (elderly group). Mortality was 25.1% higher (95% CI: 22.2-28.0%) in the elderly as compared to the non-elderly group. Death from COVID-19 was increased 6.2-fold in haemodialysis patients as compared to the mortality in the general population in a similar time frame. In the multivariate Cox regression analysis, age (hazard ratio (HR) 1.59, 95% CI: 1.31-1.93), dyspnea at presentation (HR 1.51, 95% CI: 1.11-2.04), pneumonia (HR 1.74, 95% CI: 1.10-2.73) and admission to hospital (HR 4.00, 95% CI: 1.83-8.70) were identified as independent mortality risk factors in the elderly haemodialysis population. Treatment with glucocorticoids reduced the risk of death (HR 0.68, 95% CI: 0.48-0.96). In conclusion, mortality is dramatically increased in elderly haemodialysis patients with COVID-19. Our results suggest that this high risk population should be prioritized in terms of protection and vaccination.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.